Study summary

The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).

Additional Study Details

Phase
3
Product
  • roxadustat
  • DA
  • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    334
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): Japanese

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients with Anemia? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site JP00049
      Aasahikawa, Hokkaido, Japan
      Withdrawn
      Site JP00070
      Hachioji, Tokyo, Japan
      Completed
      Site JP00024
      Minato-ku, Tokyo, Japan
      Completed
      Site JP00010
      Toyama, Toyama, Japan
      Completed
      Site JP00038
      Matsuyama, Ehime, Japan
      Completed
      Site JP00026
      Niigata, Niigata, Japan
      Completed
      Site JP00068
      Nagano, Nagano, Japan
      Completed
      Site JP00001
      Kamakura, Kanagawa, Japan
      Completed
      Site JP00064
      Sapporo, Hokkaido, Japan
      Completed
      Site JP00022
      Amagasaki, Hyogo, Japan
      Completed
      Site JP00012
      Sendai, Miyagi, Japan
      Completed
      Site JP00014
      Fukui, Fukui, Japan
      Completed
      Site JP00030
      Nagoya, Aichi, Japan
      Completed
      Site JP00015
      Koto-ku, Tokyo, Japan
      Completed
      Site JP00011
      Sakai, Osaka, Japan
      Completed
      Site JP00047
      Fujisawa, Kanagawa, Japan
      Completed
      Site JP00056
      Osaka, Osaka, Japan
      Completed
      Site JP00060
      Ota-ku, Tokyo, Japan
      Completed
      Site JP00037
      Hatsukaichi, Hiroshima, Japan
      Completed
      Site JP00066
      Nishinomiya, Hyogo, Japan
      Completed
      Site JP00045
      Kyoto, Kyoto, Japan
      Completed
      Site JP00019
      Toride, Ibaraki, Japan
      Completed
      Site JP00069
      Yao, Osaka, Japan
      Completed
      Site JP00042
      Kurume, Fukuoka, Japan
      Withdrawn
      Site JP00054
      Tsukushino, Fukuoka, Japan
      Completed
      Site JP00008
      Kitakyusyu, Fukuoka, Japan
      Completed
      Site JP00023
      Sashima-gun, Ibaraki, Japan
      Completed
      Site JP00003
      Sakura, Chiba, Japan
      Completed
      Site JP00039
      Hiroshima, Hiroshima, Japan
      Withdrawn
      Site JP00058
      Fukuoka, Fukuoka, Japan
      Completed
      Site JP00063
      Chiyoda-ku, Tokyo, Japan
      Completed
      Site JP00028
      Koga, Ibaraki, Japan
      Completed
      Site JP00041
      Tajimi, Gifu, Japan
      Completed
      Site JP00067
      Hino, Tokyo, Japan
      Completed
      Site JP00009
      Kasugai, Aichi, Japan
      Completed
      Site JP00004
      Koshigaya, Saitama, Japan
      Completed
      Site JP00034
      Oita, Oita, Japan
      Completed
      Site JP00062
      Tachikawa, Tokyo, Japan
      Completed
      Site JP00033
      Fukuoka, Fukuoka, Japan
      Completed
      Site JP00002
      Maebashi, Gunma, Japan
      Completed
      Site JP00044
      Matsuyama, Ehime, Japan
      Completed
      Site JP00025
      Adachi-ku, Tokyo, Japan
      Completed
      Site JP00061
      Osaka, Osaka, Japan
      Completed
      Site JP00021
      Toyohashi, Aichi, Japan
      Completed
      Site JP00032
      Hiroshima, Hiroshima, Japan
      Completed
      Site JP00005
      Izumisano, Osaka, Japan
      Completed
      Site JP00046
      Tsuchiura, Ibaraki, Japan
      Completed
      Site JP00055
      Okayama, Okayama, Japan
      Completed
      Site JP00050
      Kure, Hiroshima, Japan
      Completed
      Site JP00006
      Musashino, Tokyo, Japan
      Completed
      Site JP00013
      Kitakyusyu, Fukuoka, Japan
      Completed
      Site JP00053
      Naka, Ibaraki, Japan
      Completed
      Site JP00035
      Kanazawa, Ishikawa, Japan
      Completed
      Site JP00016
      Yokohama, Kanagawa, Japan
      Completed
      Site JP00057
      Kitakyusyu, Fukuoka, Japan
      Completed
      Site JP00031
      Morioka, Iwate, Japan
      Completed
      Site JP00065
      Fukuoka, Fukuoka, Japan
      Completed
      Site JP00051
      Nagoya, Aichi, Japan
      Completed
      Site JP00052
      Hitachi, Ibaraki, Japan
      Withdrawn
      Site JP00027
      Suita, Osaka, Japan
      Completed
      Site JP00040
      Kitakyusyu, Fukuoka, Japan
      Completed
      Site JP00059
      Higashiosaka, Osaka, Japan
      Completed
      Site JP00018
      Nagano, Nagano, Japan
      Completed
      Site JP00017
      Kasama, Ibaraki, Japan
      Completed
      Site JP00007
      Sapporo, Hokkaido, Japan
      Completed
      Site JP00020
      Koshigaya, Saitama, Japan
      Withdrawn
      Site JP00071
      Kagoshima, Kagoshima, Japan
      Completed
      Site JP00029
      Ageo, Saitama, Japan
      Completed
      Site JP00043
      Bunkyo-ku, Tokyo, Japan
      Completed
      Site JP00036
      Ueda, Nagano, Japan
      Completed
      Site JP00048
      Yokohama, Kanagawa, Japan

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?